EGFR and non-small cell lung carcinoma: Despite the clinical advancements achieved by amivantamab–chemotherapy in the field of advanced NSCLC harboring EGFR exon 20 insertion mutations, the high cost of amivantamab has raised concerns about its affordability and economic feasibility.